Pharmaceutical preparation

Abstract

The pharmaceutical preparation for the treatment of pancreatic insufficiency comprises a liquid administering form of enzymes.

1 . A pharmaceutical preparation comprising liquid administering form of enzymes for the treatment of digestion disorders. 
     
     
         2 . The pharmaceutical preparation according to  claim 1 , whereby the digestion disorder is a pancreatic illness. 
     
     
         3 . The pharmaceutical preparation according to  claim 2 , whereby the pancreatic illness is mucoviscidosis or pancreatitis. 
     
     
         4 . The pharmaceutical preparation according to  claim 1 , whereby the liquid administering form is a solution, a suspension or an emulsion. 
     
     
         5 . The pharmaceutical preparation according to  claim 1 , characterized in that the liquid administering form is prepared by
 a) direct fabrication of the lipase as liquid solution or   b) dissolution of the active constituent lipase in an aqueous solvent and incubated preferably at 4° C., ambient temperature and 40° C. or   c) dissolving the active constituent lipase in a non aqueous solvent or   d) suspending of the medicine in an appropriate medium, whereby the lipase suspension is a two-phase system which consists of solid lipase which is dispersed in a liquid or   e) adding of the medicine in one of the two phases of an oil/water system.   
     
     
         6 . The pharmaceutical preparation according to  claim 1 , whereby the enzyme is a bacterial lipase from the group consisting of the  Burkholderia  type, the  Pseudomonas  type, and the  Burkholderia plantarii  type. 
     
     
         7 . A method for the treatment of pancreatic insufficiency comprising the step of applying a stable solution pharmaceutical preparation comprising liquid administering form of enzymes for the treatment of digestion disorders. 
     
     
         8 . The method according to  claim 7 , wherein the pancreatic insufficiency Is mucoviscidosis or pancreatitis. 
     
     
         9 . The method according to  claim 7 , wherein the enzyme is lipase. 
     
     
         10 . The method according to  claim 7 , wherein the pharmaceutical preparation further comprises a stabilizer, an organic acid, an amino acid, a detergent, and/or sugar. 
     
     
         11 . The method according to  claim 10 , wherein the stabilizer is a salt. 
     
     
         12 . The method according to  claim 7 , whereby the liquid administering form is a solution, a suspension or an emulsion. 
     
     
         13 . The method according to  claim 7 , characterized in that the liquid administering form is prepared by
 a) direct fabrication of the lipase as liquid solution or   b) dissolution of the active constituent lipase in an aqueous solvent and incubated preferably at 4° C., ambient temperature and 40° C. or   c) dissolving the active constituent lipase in a non aqueous solvent or   d) suspending of the medicine in an appropriate medium, whereby the lipase suspension is a two-phase system which consists of solid lipase which is dispersed in a liquid or   e) adding of the medicine in one of the two phases of an oil/water system.   
     
     
         14 . The method according to  claim 7 , whereby the enzyme is a bacterial lipase from the group consisting of the  Burkholderia  type, the  Pseudomonas  type, and the  Burkholderia plantarii  type.